U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H20FN3O4.C3H6O3
Molecular Weight 451.4454
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 2
E/Z Centers 0
Charge 0
Stereo Comments C3 H6 O3

SHOW SMILES / InChI
Structure of LEVOFLOXACIN LACTATE

SMILES

CC(O)C(O)=O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4

InChI

InChIKey=ONDRRTIAGBDDKP-PPHPATTJSA-N
InChI=1S/C18H20FN3O4.C3H6O3/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;1-2(4)3(5)6/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);2,4H,1H3,(H,5,6)/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C3H6O3
Molecular Weight 90.0779
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C18H20FN3O4
Molecular Weight 361.3675
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.9 mg/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.8 mg/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.8 mg/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.85 mg/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.04 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.3 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
49.6 mg × h/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59 mg × h/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
118 mg × h/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
111 mg × h/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
19.88 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55.3 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.4 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.9 h
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.97 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.6 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.2%)
Nausea (0.6%)
Vomiting (0.5%)
Dizziness (0.3%)
Headache (0.3%)
Sources: Page: 19
AEs

AEs

AESignificanceDosePopulation
Headache 0.2%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.2%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.5%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.2%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 136 uM]
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Levofloxacin.
1999 Nov
Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum.
1999 Sep
Activity of moxifloxacin against mycobacteria.
1999 Sep
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
2000 Dec
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
2000 Feb
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.
2000 Oct
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
2001 Apr
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
2001 Apr
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.
2001 Apr
[Injectable quinolones].
2001 Apr
Quinolones alter defense reactions mediated by macrophages.
2001 Feb
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
2001 Feb
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
2001 Feb
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
2001 Feb
In vitro activity of new quinolones against Clostridium difficile.
2001 Feb
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.
2001 Feb
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
2001 Feb 15
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.
2001 Jan
Nosocomial pneumonia. Diagnostic and therapeutic considerations.
2001 Jan
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
2001 Jan
A case of continuous ambulatory peritoneal dialysis peritonitis with an uncommon organism and an atypical clinical course.
2001 Jan
Use of a recombinant strain of Mycobacterium avium expressing beta-galactosidase to evaluate the activities of antimycobacterial agents inside macrophages.
2001 Jan
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].
2001 Jan-Feb
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.
2001 Jul
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
2001 Jul
Activity of levofloxacin and ciprofloxacin against urinary pathogens.
2001 Jul
Levofloxacin failure in a patient with pneumococcal pneumonia.
2001 Jun
Treatment of tularemia with levofloxacin.
2001 Mar
A case of renal involvement in persistent immune activation caused by chlamydial salpingitis.
2001 Mar
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
2001 Mar
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
2001 May
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
2001 May
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
2001 May 15
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
2001 Spring
Patents

Sample Use Guides

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration: Other
In Vitro Use Guide
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class Chemical
Created
by admin
on Thu Jul 06 13:52:13 UTC 2023
Edited
by admin
on Thu Jul 06 13:52:13 UTC 2023
Record UNII
NHR291QA18
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOFLOXACIN LACTATE
WHO-DD  
Common Name English
7H-1,4-OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, COMPD. WITH 2-HYDROXYPROPANOIC ACID (1:1)
Systematic Name English
PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH (3S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID (1:1)
Systematic Name English
(3S)-9-FLUORO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-2,3-DIHYDRO-7H-(1,4)OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID - 2-HYDROXYPROPANOIC ACID (1:1)
Systematic Name English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, MONO(2-HYDROXYPROPANOATE)
Systematic Name English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, 2-HYDROXYPROPANOATE (1:1)
Systematic Name English
Levofloxacin Lactate [WHO-DD]
Common Name English
Code System Code Type Description
CAS
97853-07-1
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
PUBCHEM
25119532
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
EVMPD
SUB121291
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID00648769
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
CAS
294662-18-3
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
FDA UNII
NHR291QA18
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
SMS_ID
100000144586
Created by admin on Thu Jul 06 13:52:13 UTC 2023 , Edited by admin on Thu Jul 06 13:52:13 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY